Objective:To determine the effects of tamoxifen on the growth and differentiation of normal human cervical cells and compare those effects with those of a synthetic estrogen, diethylstilbestrol (DES). In addition, the effects of these compounds on immortalized cervical cells and cervical tumor cells were ascertained.
Methods:Growth curves were used to determine the effects on cell proliferation. The expression of several proteins was used to determine the effects on cell differentiation. Binding assays and Western analysis were used to determine estrogen receptor levels.
Results:Both tamoxifen and DES inhibited the proliferation of normal cervical cells. This growth inhibition was coincident with an increase in cell differentiation as determined by cornified envelope formation. The increase in envelope number was not accompanied by an increase in involucrin or cornifin, two protein precursors of the envelope. The activity of transglutaminase, which enzymatically incorporates precursor proteins into the envelope, was not stimulated following treatment. Diethylstilbestrol did not alter the growth or differentiation of the human papillomavirus 16-immortalized cell line ECE16-1 or any of the cervical tumor cell lines. Of all the immortalized or cancer cell lines, only Caski cells were growth inhibited by tamoxifen. Normal ectocervical epithelial cells and Caski cells expressed the high-affinity 56-kDa estrogen receptor, but 3H-estradiol binding was not detected in cell extracts from either ME180 or ECE16-1- cells. Nevertheless, extracts from ME180 cells contained on immunoreactive band at the appropriate molecular weight for the estrogen receptor.
Conclusions:These results suggest that tamoxifen and DES act similarly in normal cervical cells to promote cervical cell differentiation. However, because Caski cell growth was inhibited by tamoxifen and not DES, the effects of tamoxifen in thse cells may be mediated by non-estrogen receptor mechanisms.
1. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet1994;343:1318-1321.
2.
2. Jordan VC, Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Res Treat1990;15:125-136.
3.
3. van den Loedjik CDMA, Blankenstein MA, Thijssen JHH. Speculation on the mechanism of action of triphenylethylene antioestrogens. Biochemical Pharmacology1994;47:1927-1937.
4.
4. Gronemeyr H, Benhamou B, Berry M, et al. Mechanisms of antihormone action. J Steroid Biochem Mol Biol1992;41:217-221.
5.
5. Jordan VC, Murphy CS. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev1988;11:578-610.
6.
6. Kuiper GG, Brinkmann AO. Steroid hormone receptor phosphorylation: Is there a physiological role?Mol Cell Endocrinol1994;100:103-107.
7.
7. Fuqua SA, Allred DC, Auchus RJ. Expression of estrogen receptor variants. J Cell Biochem Suppl1993;17G:194-197.
8.
8. Katzenellenbogen BS, Bhardwaj B, Fang H, et al. Hormone binding and transcription activation by estrogen receptors: Analyses using mammalian and yeast systems. J Steroid Biochem Mol Biol1993;47:39-48.
9.
9. Rorke EA, Kendra KL, Katzenellenbogen BS. Relationships among uterine growth, ornithine decarboxylase activity and polyamine levels: Studies with estradiol and antiestrogens. Mol Cell Endocrinol1984;38:31-38.
10.
10. Roke EA, Katzenellenbogen BS. Comparative effects of estrogen and antiestrogens on enzyme activities in R3230AC rat mammary tumors and uteri of tumor-bearing animals. Cancer Res1980;40:3158-3162.
11.
11. van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet1994;343:448-452.
12.
12. Wiseman LR, McTavish D. Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. Drugs Aging1994;4:238-256.
13.
13. Ferenczy A, Winkler B. Anatomy and histology of the cervix. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract. 3rd ed.New York: Springer-Verlag, 1987:141-187.
14.
14. Sedlis A, Chen P. Cytology. In: Droegemueller W, Sciarra JJ, eds. Gynecology and obstetrics. Philadelphia: Harper and Row, 1987:1-67.
15.
15. Reagan JW, Fu YS. The uterine cervix. In: Silverberg SG, ed. Principles and practice of surgical pathology. New York: Wiley, 1983:1219-1263.
16.
16. Grenman S, Shapira A, Carey TE. In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen. Gynecol Oncol1988;30:228-228.
17.
17. Stanley MA, Crowcroft NS, Quigley JP, Parkinson EK. Responses of human cervical keratinocytes in vitro to tumour promoters and diethylstrilboestrol. Carcinogenesis1985;6:1011-1015.
18.
18. Gorodeski GI, Eckert RL, Utian WH, Rorke EA. Maintenance of in vivo-like keratin expression, sex steroid responsiveness, and estrogen receptor expression in cultured human ectocervical epithelial cells. Endocrinology1990;126:399-406.
19.
19. Gorodeski GI, Eckert RL, Utian WH, Sheean L, Rorke EA. Cultured human ectocervical epithelial cell differentiation is regulated by the combined direct actions of sex steroids, glucocorticoids, and retinoids, J Clin Endocrinol Metab1990;70:1624-1630.
20.
20. Gorodeski GI, Romero MF, Hopfer U, Rorke E, Utian WH, Eckert RL, Human uterine cervical epithelial cells grown on permeable support—A new model for the study of differentiation. Differentiation1994;56:107-118.
21.
21. Agarwal C, Rorke Ea, Irwin JC, Eckert RL. Immortalization by human papillomavirus type 16 alters retinoid regulation of human ectocervical epithelial cell differentiation. Cancer Res1991;51:3892-3899.
22.
22. Sizemore N, Rorke EA. Human papillomavirus 16 immortalization of normal human ectocervical epithelial cells alters retinoic acid regulation of cell growth and epidermal growth factor receptor expression. Cancer Res1993;53:4511-4517.
23.
23. Kasturi L, Sizemore N, Eckert RL, Martin K, Rorke EA. Calcium modulates cornified envelope formation, involucrin content, and transglutaminase activity in cultured human ectocervical epithelial cells. Exp Cell Res1993;205:84-90.
24.
24. Choo CK, Rorke EA, Eckert RL. Calcium regulates the differentiation of human papillomavirus type 16 (HPV16) immortalized ectocervical epithelial cells, but not the expression of the papillomavirus E6 and E7 oncogenes. Exp Cell Res1993;208:161-169.
25.
25. Rayter Z, Gazet JC, Shepherd J, Trott PA, et al. Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol1993;123:146-157.
26.
26. Vargas-Roig LM, Fotfi H, Olcese JE, Lo-Castro G, Ciocca DR. Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res1993;13:2457-2463.
27.
27. Scambia G, Panici PB, Baiocchi B, et al. Steroid hormone receptors in carcinoma of the cervix: Lack of response to an antiestrogen. Gynecol Oncol1990;37:323-326.
28.
28. Welty TK, Zephier N, Schweigman K, Blake B, Leonardson G. Cancer risk factors in three Sioux tribes. Use of the Indian-specific health risk appraisal for data collection and analysis. Alaska Med1993;35:265-272.
29.
29. Davidson M, Schnitzer PG, Bullkow LR, et al. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaska Native women. J Infect Dis1994;169:792-800.
30.
30. Munoz N, Bosch FX, de Sanjose S, Shah KV. The role of HPV in the etiology of cervical cancer. Mutat Res1994;305:293-301.
31.
31. Imman GJ, Cook ID, Lau RK. Human papillomaviruses, tumour suppressor genes and cervical cancer. Int J STD AIDS1993;4:128-134.
32.
32. zur Hausen H. Papillomaviruses in human cancers. Mol Carcinogen1988;1:147-150.
33.
33. Schmeider A, Holz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer1987;40;198-203.
34.
34. Gorodeski GI, Eckert RL, Utian WH, Sheean L, Rorke EA. Retinoids, sex steroids and glucocorticoids regulate ectocervical cell envelope formation but not the level of the envelope precursor, involucrin. Differentiation1989;42:75-80.
35.
35. Sizemore N, Kasturi L, Gorodeski G, Eckert RL, Jetten AM, Rorke EA. Retinoid regulation of human ectocervical epithelial cell transglutaminase activity and keratin gene expression. Differentiation1993;54:219-225.
36.
36. Rice RH, Green H. Presence in human epidermal cells of a soluble protein precursor of the cross-linked envelope: Activation of the cross-linking by calcium ions. Cell1979;18:681-694.
37.
37. Marvin KW, George MD, Fujimoto W, Saunders NA, Bernacki SH, Jetten AM. Cornifin, a cross-linked envelope precursor in keratinocytes that is down-regulated by retinoids. Proc Natl Acad Sci U S A1992;89:11026-11030.
38.
38. Furlow JD, Ahrens H, Mueller GC, Gorski J. Antisera to a synthetic peptide recognize native and denatured rat estrogen receptors. Endocrinology1990;127:1028-1032.
39.
39. Eckert RL, Mullick A, Rorke EA, Katzenellenbogen BS. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology1984;114:629-637.
40.
40. Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K. Antiestrogen pharmacology and mechanism of action. J Steroid Biochem1983;19:59-68.
41.
41. Lazier CB, Bapat BV. Antiestrogen binding sites: General and comparative properties. J Steroid Biochem1988;31:665-669.
42.
42. Rayter Z, Gazet JC, Shepherd J, et al. Gynaecological cytology and pelvic ultrasonography in patients with breast cancer taking tamoxifen compared with controls. Eur J Surg Oncol1994;20:134-140.
43.
43. Rorke EA, Katzenellenbogen BS. Antitumor activities and estrogen receptor interactions of the metabolites of the antiestrogens C1628 and U23, 469 inthe 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor system. Cancer Res1981;41:1257-1262.
44.
44. Sanborn BM, Kuo HS, Held B. Estrogen and progestogen binding site concentrations in human endometrium and cervix throughout the menstrual cycle and in tissue from women taking oral contraceptives. J Steroid Biochem1978;9:951-955.
45.
45. Nonogaki H, Fujii S, Konishi I, et al. Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix. Cancer1990;66:2620-2627.
46.
46. Konishi I, Fujii S, Nonogaki H, Nanbu Y, Iwai T, Mori T. Immunohistochemical analysis of estrogen receptors, progesterone receptors, Ki-67 antigen, and human papillomavirus DNA in normal and neoplastic epithelium of the uterine cervix. Cancer1991;68:1340-1350.
47.
47. Eckert RL, Roke EA. Molecular biology of keratinocyte differentiation. Environ Health Perspect1989;80:109-116.
48.
48. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: Multifunctional cross-linking enzymes that stabilize tissues. FASEB J1991;5:3071-3077.
49.
49. Eckert RL. Structure, function and differentiation of the keratinocyte. Physiologic Rev1989;69:1316-1346.
50.
50. Warhol MJ, Antonioli DA, Pinkus GS, Burke K, Rice RH. Immunoperoxidase staining for involucrin: A potential diagnostic aid in cervicovaginal pathology. Hum Pathol1982;13:1095-1099.
51.
51. Parenteau NL, Pilato A, Rice RH. Induction of keratinocyte type-I transglutaminase in epithelial cells of the rat. Differentiation1986;33:130-141.
52.
52. Warhol MJ, Pinkus GS, Rice RH, et al. Papillomavirus infection of the cervix. III: Relationship of the presence of vital structural proteins to the expression of involucrin. Int J Gynecol Pathol1984;3:71-81.
53.
53. Rice RH, Thacher SM. Involucrin: A constituent of cross-linked envelops and marker of squamous maturation. In: Bereiter-Hahn J, Matoltsy AG, Richards KS, eds. Biology of the integument. Vol. 2. Vertebrates. Berlin Heidelberg: Springer-Verlag, 1986;752-761.
54.
54. Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS. High affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature1980;288:273-275.
55.
55. O'Brian CA, Ward NE, Anderson BW. Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J Natl Cancer Inst1988;80:1628-1633.
